In a positive development towards the development of COVID-19 vaccine, Hyderabad-based Bharat Biotech has announced that animal trials of its vaccine candidate ‘Covaxin’ have been successful.
Bharat Biotech said the results demonstrated protective efficacy of the vaccine in a live viral challenge model. It said that the data from the study on primates substantiates the immunogenicity of the vaccine candidate.
Bharat Biotech proudly announces the animal study results of COVAXIN™ – These results demonstrate the protective efficacy in a live viral challenge model.
Read more about the results here – https://t.co/f81JUSfWpD@icmr_niv #BharatBiotech #COVAXIN #Safety #Vaccine #SARSCoV2 pic.twitter.com/fva1SOcLOr
— BharatBiotech (@BharatBiotech) September 11, 2020
A two-dose vaccination regimen of inactivated coronavirus vaccine candidates was administered in 20 rhesus macaques (divided into four groups equally).
ALSO READ: COVID-19 | Top 10 global developments this Saturday morning
One group was administered with placebo, while three groups were immunized with 3 different vaccine candidates at 0 and 14 days. All the macaques were exposed to viral challenge 14 days after the 2nd dose.
Remarkable immunogenicity and protective efficacy of BBV152, an inactivated SARS-CoV-2 vaccine in rhesus macaques https://t.co/b82dA6QlcW ICMR-NIV made very good effort to demonstrate potential immunogenicity in non-human✌️ Primate with BBV152. ! @ICMRDELHI @drharshvardhan
— Dinesh kumar (@Dineshk38263974) September 11, 2020
Results showed protective efficacy, increasing coronavirus specific IgG and neutralizing antibodies, reducing replication of the virus in the nasal cavity, throat, and lung tissues of monkey.
No evidence of pneumonia was observed by histopathological examination in vaccinated groups, unlike the placebo group.
BBIL’s #Covaxin(BBV152) found protective in Macaques: A two-dose vaccination regimen using 3µg dose of the vaccine with adjuvant B induce a significant immune response and provide effective protection in macaques challenged with #SARSCoV2 https://t.co/FgSnD2eCmA pic.twitter.com/hQHh2klAnX
— Vipin M. Vashishtha (@vipintukur) September 11, 2020
Adverse events were not seen in animals immunized with a two-dose vaccination regimen.
‘COVAXIN’ ANIMAL TRIALS: ALL YOU NEED TO KNOW
- A 2-dose vaccination regimen of inactivated SARS-CoV-2 vaccine candidates was administered in 20 rhesus macaques (divided into four groups equally).
- One group was administered with placebo, while three groups were immunized with 3 different vaccine candidates at 0 and 14 days. All the macaques were exposed to viral challenge 14 days after the 2nd dose.
- The results showed protective efficacy, increasing SARS-CoV-2 specific IgG and neutralizing antibodies, reducing replication of the virus in the nasal cavity, throat, and lung tissues of monkey.
- No evidence of pneumonia was observed by histopathological examination in vaccinated groups, unlike the placebo group
- Adverse events were not seen in animals immunized with a two-dose vaccination regimen.
“We report the two-dose vaccination regimen of inactivated SARS-CoV-2 vaccine candidates found to induce a strong immune response and protection of animals from the infection of SARS-CoV-2,” Bharat Biotech said in its report.
Meanwhile, drug regulator DCGI has directed Pune-based Serum Institute of India (SII) to suspend recruitment in its clinical trials of AstraZeneca’s potential COVID-19 vaccine in the country till further orders.
ALSO READ: AstraZeneca puts COVID-19 vaccine trials on hold after unexpected illness in volunteer
Click here for Latest News updates and viral videos on our AI-powered smart news
For viral videos and Latest trends subscribe to NewsMobile YouTube Channel and Follow us on Instagram
